Uncategorized

Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of slowing down as analysts gear up for a year that will test the oral market and provide key data on novel mechanisms.

The administration’s direct-to-consumer pharmaceutical sales platform will offer products from Eli Lilly, Pfizer, Novo Nordisk, Amgen and more at a discount, though the impact of such pricing remains to be seen.

After taking a $245 million hit from the levies in 2025, CFO James Saccaro said the company plans more actions to mitigate the effects of tariffs in 2026, including shifting its supply chain.

Cigna is hoping the settlement it reached with regulators paired with recent legislation will mollify calls to reform PBMs — without affecting Express Scripts’ profitability.

The vendor could prove a significant competitor in the AI notetaking space, given Epic’s leading market share in electronic health records.

Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy continues to struggle with uptake.

Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.

The 510(k) decision clears the device for use with ultra-rapid-acting insulins from Eli Lilly and Novo Nordisk.

Visit volume for physicians who scaled back on appointments declined nearly 33%, but their EHR time only fell 21%, according to a study published in Health Affairs.

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.